buformin oral antidiabetic drug biguanide class chemically related metformin phenformin buformin marketed german pharmaceutical company grünenthal silubin buformin hydrochloride fine white slightly yellow crystalline odorless powder weakly acidic bitter taste melting point strong base freely soluble water methanol ethanol insoluble chloroform toxicity guinea pig subcutaneous mgkg mouse intraperitoneal mgkg mgkg log octanolwater partition coefficient log p water solubility mgl vapor pressure mm hg est henrys law constant est atmospheric oh rate constant buformin delays absorption glucose gastrointestinal tract increases insulin sensitivity glucose uptake cells inhibits synthesis glucose liver buformin biguanides hypoglycemic rather antihyperglycemic agents produce hypoglycemia instead reduce basal postprandial hyperglycemia biguanides may antagonize action glucagon thus reducing fasting glucose oral administration mg buformin volunteers almost applied quantity recovered urine rate constant elimination found per hr buformin strong base pka absorbed stomach intravenous injection mgkg initial serum concentration µgml serum level urinary elimination rate linearly man oral administration mg maximum serum concentration µgml buformin eliminated average halflife h dose administered found excreted unchanged buformin metabolized humans bioavailability oral buformin biguanides binding plasma proteins absent daily dose buformin mg buformin also available sustained release preparation silubin retard still sold romania side effects encountered anorexia nausea diarrhea metallic taste weight loss use contraindicated diabetic coma ketoacidosis severe infection trauma conditions buformin unlikely control hyperglycemia renal hepatic impairment heart failure recent myocardial infarct dehydration alcoholism conditions likely predispose lactic acidosis buformin withdrawn market many countries due elevated risk causing lactic acidosis although us never sold buformin still available prescribed romania timed release silubin retard sold zentiva japan sold nichiiko pharmaceutical co ltd dibetos tablets containing mg buformin lactic acidosis occurred patients buformin plasma level greater µgml rare patients normal renal one report toxic oral dose mgday patients developed lactic acidosis buformin another group patients mgday develop lactic acidosis buformin along phenformin metformin inhibits growth development anticancer property drugs due ability disrupt warburg effect revert cytosolic glycolysis characteristic cancer cells normal oxidation pyruvate metformin reduces liver glucose production diabetics disrupts warburg effect cancer ampk activation inhibition mtor buformin decreased cancer incidence multiplicity burden chemically induced rat mammary cancer whereas metformin phenformin statistically significant effect carcinogenic process relative control buformin also exhibits antiproliferative antiinvasive effects endometrial cancer lung cancer cervical cancer biguanides first noted active influenza studies confirmed antiviral activity buformin especially potently antiviral vaccinia buformin metabolic antiviral inhibits mtor pathway used influenza middle east respiratory syndromerelated buformin synthesized oral antidiabetic buformin obtained reaction butylamine httpsenwikipediaorgwikibuformin